Atezolizumab Caused Pityriasis Lichenoides-Like Drug Eruption Treated with Narrowband Ultraviolet B

Megan M. Perez, Sebastian Otto-Meyer, Cuong Viet Nguyen, Lida Zheng, Jennifer Choi, Lauren Marie Guggina*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Pityriasis lichenoides is a rare cutaneous disease that exists along a spectrum with acute and chronic features. The acute form, pityriasis lichenoides et varioliformis acuta (PLEVA), presents as a sudden onset scaly and often crusted, erythematous papular eruption. The chronic form, pityriasis lichenoides chronica, presents similarly but with a more indolent onset. This inflammatory condition can have numerous triggers, including infections and medications. However, checkpoint inhibitors, despite being associated with a wide variety of cutaneous adverse events, have only rarely been associated with a pityriasis lichenoides-like eruption. We report a case of drug-induced pityriasis lichenoides-like eruption secondary to checkpoint inhibitor atezolizumab that was successfully treated with narrowband ultraviolet B (NBUVB) light. To our knowledge, this is the first case of an atezolizumab-induced pityriasis lichenoides which responded well to NBUVB.

Original languageEnglish (US)
Pages (from-to)143-146
Number of pages4
JournalSKIN: Journal of Cutaneous Medicine
Issue number2
StatePublished - Mar 6 2021

ASJC Scopus subject areas

  • Dermatology


Dive into the research topics of 'Atezolizumab Caused Pityriasis Lichenoides-Like Drug Eruption Treated with Narrowband Ultraviolet B'. Together they form a unique fingerprint.

Cite this